| __timestamp | Corcept Therapeutics Incorporated | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 882000 | 17293000 |
| Thursday, January 1, 2015 | 1361000 | 26470000 |
| Friday, January 1, 2016 | 2058000 | 28307000 |
| Sunday, January 1, 2017 | 3554000 | 30354000 |
| Monday, January 1, 2018 | 5215000 | 32160000 |
| Tuesday, January 1, 2019 | 5504000 | 37571000 |
| Wednesday, January 1, 2020 | 5582000 | 39951000 |
| Friday, January 1, 2021 | 5281000 | 50159000 |
| Saturday, January 1, 2022 | 5385000 | 54577000 |
| Sunday, January 1, 2023 | 6481000 | 61940000 |
Unleashing insights
In the competitive landscape of biotechnology, understanding cost structures is crucial. Corcept Therapeutics Incorporated and Vericel Corporation, two prominent players, have shown distinct trends in their cost of revenue from 2014 to 2023. Corcept's cost of revenue has grown steadily, starting at just under $1 million in 2014 and reaching approximately $6.5 million by 2023. This represents a growth of over 600% in a decade. Meanwhile, Vericel's cost of revenue began at around $17 million in 2014, surging to nearly $62 million by 2023, marking a 260% increase.
These figures highlight the differing scales and growth trajectories of the two companies. While both have expanded, Vericel's larger base and more substantial growth suggest a more aggressive expansion strategy. Investors and industry analysts should consider these trends when evaluating the financial health and strategic direction of these companies.
Cost of Revenue: Key Insights for Novo Nordisk A/S and Vericel Corporation
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Vericel Corporation
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Vericel Corporation
Cost of Revenue Comparison: BeiGene, Ltd. vs Vericel Corporation
Comparing Cost of Revenue Efficiency: Viatris Inc. vs Corcept Therapeutics Incorporated
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Vericel Corporation's Expenses
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Bausch Health Companies Inc.
Cost Insights: Breaking Down Veracyte, Inc. and Vericel Corporation's Expenses
Cost of Revenue Trends: MorphoSys AG vs Vericel Corporation
Cost of Revenue Trends: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Vericel Corporation vs Geron Corporation: Efficiency in Cost of Revenue Explored